JP5654704B1 - Ophthalmic composition - Google Patents

Abstract

To provide an ophthalmic composition capable of improving the effect of suppressing the adsorption of foreign matter to the cornea and alleviating the feeling of foreign matter in the eye.
An ophthalmic composition comprising polysorbate 80 and a refreshing agent, wherein the polydispersity of polysorbate 80 in the ophthalmic composition is 1.00 to 1.26.
[Selection figure] None

Description

  The present invention relates to ophthalmic compositions.

  The cornea is a tissue composed of five layers of the corneal epithelium, Bowman's membrane, corneal stroma, Descemet's membrane, and corneal endothelium in order from the outside, and is configured on the outermost surface of the eyeball. The cornea is easily invaded by various foreign substances such as antigens, microorganisms, and dust due to anatomical features that are in direct contact with the outside world. Cornea perception is one of the most sensitive perceptions of human pain.

JP 2011-098989 A

  When foreign substances such as dust and pollen enter the corneal epithelium, symptoms such as foreign body sensation and eye pain may appear. In other words, it is important to improve the quality of life by removing indefinite complaints by improving the invasion of foreign matter to the surface of the eyeball and the feeling of foreign matter originating from it.

  As a countermeasure against the intrusion of such foreign matter, an eyewash containing a carboxyvinyl polymer and a monoterpene and removing a cosmetic or pollen from the eyeball or eyelid and using a single eyewash of 500 μL or more is seen. (Patent Document 1).

  This invention is made | formed in view of the said situation, and it aims at providing the ophthalmic composition which can improve the inhibitory effect of the foreign material adsorption | suction to a cornea, and can relieve the foreign body feeling of an eye.

  As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that when a polysorbate 80 having a relatively high polydispersity in an ophthalmic composition and a cooling agent coexist, the effect of suppressing the adsorption of foreign substances on the cornea is obtained. Although inhibited, it was newly confirmed that when polysorbate 80 having a relatively low polydispersity in the ophthalmic composition and a cooling agent coexist, the effect of suppressing the adsorption of foreign substances to the cornea is improved. That is, an ophthalmic composition containing (A) polysorbate 80 (hereinafter sometimes referred to as “component (A)”) and (B) a cooling agent (hereinafter sometimes referred to as “component (B)”). The ophthalmic composition in which the polydispersity of the component (A) in the ophthalmic composition is 1.00 to 1.26 suppresses foreign matter adsorption to the cornea and relieves the feeling of foreign matter in the eye. I found out. The inventors of the present invention are the first to focus on the polydispersity of polysorbate 80 in the ophthalmic composition with respect to the suppression of the foreign matter adsorption to the cornea and the influence on the foreign matter sensation of the eye. Based on these findings, the present inventors have completed the present invention.

  That is, this invention provides the ophthalmic composition of the following aspect. The details of the mechanism for suppressing the adsorption of foreign substances to the cornea or alleviating the feeling of foreign substances in the eyes by setting the polydispersity of polysorbate 80 within the following range have not been clarified. One possible reason is that the micelle structure differs slightly from that of the agent, which affects the affinity between corneal epithelial cells and foreign substances.

That is, the present invention provides the following [1] to [7].
[1] Polysorbate 80;
A cooling agent,
An ophthalmic composition comprising:
An ophthalmic composition having a polydispersity of the polysorbate 80 in the ophthalmic composition of 1.00 to 1.26;
[2] The ophthalmic composition according to the above [1], wherein the refreshing agent comprises at least one selected from the group consisting of menthol, camphor, borneol and geraniol;
[3] The above [1] or [2], wherein the total content of the refreshing agent is 0.0001 to 100 parts by mass with respect to 1 part by mass of the polysorbate 80 contained in the ophthalmic composition. ] The ophthalmic composition according to
[4] The ophthalmic composition according to any one of the above [1] to [3], which is an eye drop;
[5] The ophthalmic composition according to any one of [1] to [4], which is for a soft contact lens;
[6] A foreign substance sensation mitigating agent comprising the ophthalmic composition according to any one of [1] to [5] above;
[7] A method of imparting a mitigating action of a foreign body sensation to an ophthalmic composition by blending polysorbate 80 and a refreshing agent,
The method wherein the polydispersity of the polysorbate 80 in the ophthalmic composition is from 1.00 to 1.26.

  ADVANTAGE OF THE INVENTION According to this invention, it becomes possible to provide the ophthalmic composition which can improve the inhibitory effect of the foreign material adsorption | suction to a cornea, and can relieve the foreign body feeling of an eye. Specifically, it is possible to provide an ophthalmic composition that reduces the adsorption of foreign matter such as air pollutants and cosmetics to the cornea to dust, pollen, eyes, and the like, and reduces the feeling of foreign matter in the eye.

  Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the following embodiments. In the present specification, the unit of content “%” means “w / v%” and is synonymous with “g / 100 mL”.

  In the present specification, the “foreign substance sensation” means a subjective symptom (discomfort, irritation) of an eye that is caused by the adsorption of a foreign substance to the cornea. Examples of such subjective symptoms include a subjective symptom in which something hits the eye when blinking, and a subjective symptom in which something is stuck in the eye. Accordingly, the present inventors have focused on suppressing the adsorption of foreign matter to the cornea and improving subjective symptoms in order to alleviate the feeling of foreign matter in the eye. In particular, suppressing the adsorption of foreign matter to the cornea has a preventive effect on the feeling of foreign matter in the eye.

The ophthalmic composition according to the present embodiment (hereinafter sometimes simply referred to as “ophthalmic composition”) contains (A) polysorbate 80 and (B) a cooling agent, and includes the above-described ophthalmic composition. The polydispersity of polysorbate 80 is 1.00 to 1.26.

(Ophthalmic composition)
(A) Component The polysorbate 80 according to the present embodiment (hereinafter sometimes simply referred to as “polysorbate 80”) is not particularly limited as long as the polydispersity is 1.00 to 1.26. The said polysorbate 80 can be obtained by measuring the polysorbate 80 obtained as a commercial item with the measuring method mentioned later, and selecting the polysorbate 80 whose polydispersity is 1.00-1.26.

Or the polysorbate 80 which is polydispersity 1.00-1.26 can be obtained by further fractionating or refine | purifying the polysorbate 80 obtained as a commercial item by a well-known method. The method for fractionation or purification of the polysorbate 80 is not particularly limited, but purification using an ion exchange resin, activated carbon or adsorbent, steam deodorization, decolorization, dehydration and desolvation, filter filtration, cake filtration, centrifugation, sedimentation A method such as removal or a combination of two or more of these can be used. These fractionation or purification methods can be carried out if it is necessary to eliminate adverse effects on polydispersity measurement errors and the like. Other fractionation methods of the polysorbate 80 include, for example, a membrane filtration method, a distillation method, an extraction method or washing with an organic solvent, a reprecipitation method, a liquid / liquid separation method, or two or more of these methods. A combined method is mentioned. Specific examples include the following membrane filtration methods. The molecular weight and polydispersity of polysorbate 80 obtained as a commercial product are measured by the size exclusion chromatography (SEC) method described later, and an appropriate ultrafiltration membrane with a rejection rate close to 90% and a permeation flux is selected. . A commercially available filtration membrane can be used (for example, UF disk PLBC Ultracell RC 3K NMWL (molecular weight cut-off 3 KDa, cellulose membrane) (manufactured by Millipore Corporation)). A pressure of 0.5 to 200 Pa is applied according to the limit pressure of the filtration membrane. Polysorbate 80 having a polydispersity of 1.00 to 1.26 can be obtained by fractionation based on the weight average molecular weight and the Z average molecular weight.
As other purification methods of the polysorbate 80, for example, crystallization, resin chromatography, a method of directly drying the reaction solution with a spray dryer and pulverizing, a method of removing by steam distillation, an organic solvent and water were used. Examples include liquid-liquid extraction methods. Specific examples of the purification method include the following methods. First, polysorbate 80 is dissolved in methanol, the molecular weight at the critical micelle concentration is measured by a light scattering method, and the fractional molecular weight of the ultrafiltration membrane is determined. Next, membrane filtration is performed under conditions of a flow rate of 0.5 to 10 ml / min and a pressure of 0.1 to 20 bar.

  Or although the manufacturing method in particular of the said polysorbate 80 is not restrict | limited, The polysorbate 80 whose polydispersity is 1.00-1.26 can be obtained with the following method. It is produced by adding ethylene oxide to a mixture obtained by partially esterifying sorbitol and / or sorbitol anhydride with a fatty acid mainly composed of oleic acid. The ester reaction can be carried out using sorbitan and a fatty acid under a basic catalyst, under an inert gas stream, at normal pressure or under reduced pressure, usually at a temperature of 150 to 280 ° C. After the reaction, neutralization is performed by adding a small amount of acid sufficient to deactivate the basic catalyst. The raw material sorbitol can be obtained by high-pressure hydrogen reduction of glucose, and a commercially available product may be used (for example, sorbitol D-70 (manufactured by Towa Kasei Kogyo Co., Ltd.), sorbitol S (Japan) Kenken Chemical Co., Ltd.)). Sorbitan can be obtained by dehydrating cyclization of sorbitol, and commercially available products may be used (for example, those manufactured by Toei Chemical Co., Ltd.). Alternatively, commercially available sorbitan oleate can also be used. The step of adding ethylene oxide to sorbitan fatty acid ester uses a catalyst such as an alkali metal catalyst and fatty acid soap. The manufactured polysorbate 80 can be filtered. The basic catalyst in the ester reaction includes alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide, alkali metal carbonates such as sodium carbonate and potassium carbonate, alkali metal hydrogen carbonates, alkali metals, Alkaline compounds such as alkaline earth metals, alkaline earth metal oxides, alkaline earth metal hydroxides, other metals, oxides thereof, and mixtures thereof, and phosphorous acid (salts) and / or hypoxia Combination with phosphoric acid (salt). Moreover, nitrogen or argon can be used for the inert gas used, for example. Examples of the metal catalyst for adding ethylene oxide to the product after the ester reaction include potassium hydroxide, sodium hydroxide, sodium methylate and the like. Polysorbate 80 having a polydispersity of 1.00 to 1.26 can be obtained by further fractionating or purifying the polysorbate 80 thus obtained by a known method.

  Furthermore, the polysorbate 80 whose polydispersity is 1.00-1.26 can also be prepared by mixing the 2 or more types of polysorbate 80 from which polydispersion differs.

  The ophthalmic composition according to this embodiment has a polysorbate 80 with a polydispersity of 1.00 to 1.26 obtained as a commercial product, and a polydispersity obtained by purifying a commercial product with the purification method described above. Manufactured by a method comprising a step of blending a polysorbate 80 having a polydispersity of 1.00 to 1.26 and a polysorbate 80 having a polydispersity of 1.00 to 1.26, which is 00 to 1.26. Also good. Moreover, you may manufacture by the method including the process of mix | blending 2 or more types of polysorbate 80 obtained by the different method, and a refreshing agent. By producing in this way, the polydispersity of polysorbate 80 in the ophthalmic composition can be made to be 1.00 to 1.26.

  The polydispersity of polysorbate 80 is 1.00 to 1.26, preferably 1.00 to 1.23, more preferably 1.00 to 1.21, and 1.00 to 1 Even more preferably, .19. By setting the polydispersity in such a range, the effect of the present invention of suppressing the adsorption of foreign matter to the cornea or alleviating the feeling of foreign matter of the eye can be exhibited more remarkably.

The weight average molecular weight of the polysorbate 80 is not particularly limited, but is preferably 1200 to 3200, more preferably 1300 to 3000. Moreover, the Z average molecular weight of polysorbate 80 is not particularly limited, but is preferably in the range of 1300 to 3500, more preferably 1400 to 3300.
By setting the weight average molecular weight and the Z average molecular weight of the polysorbate 80 in the ranges as described above, the effects of the present invention such as suppression of foreign matter adsorption to the cornea or alleviation of the feeling of foreign matter in the eye can be exhibited more remarkably.
In addition, the measuring method and calculation method of a weight average molecular weight, Z average molecular weight, and polydispersity are as follows.

The polydispersity of polysorbate 80 is defined as M _z / M _w . M _z represents the Z average molecular weight, and M _w represents the weight average molecular weight.

  Various molecular weight measurement methods such as liquid chromatography, ultracentrifugation, light scattering, and intrinsic viscosity are known. Depending on the measurement method, the type of average molecular weight obtained such as weight average molecular weight, Z average molecular weight or the like, or the measurable molecular weight range is different. The weight average molecular weight, Z average molecular weight and polydispersity defined by the present invention are measured by size exclusion chromatography (SEC). The SEC method can measure a weight average molecular weight, a Z average molecular weight, and a polydispersity, and is easy to operate. Therefore, the SEC method is most widely used for measuring high molecular compounds, oligomers, and the like.

The SEC method uses a column packed with a gel with pores, and has a mechanism for separation by different elution times due to differences in the moving distance in the column depending on the molecular size in the sample solution. Average molecular weights such as M _z and M _w are calculated based on a calibration curve prepared with a standard substance having a known molecular weight. Thus, since the Z average molecular weight, weight average molecular weight and polydispersity obtained by the SEC method are relative values obtained by performing molecular weight calibration using a standard substance, the same standard substance can be used. Can only be obtained. Therefore, the SEC method of the present invention is defined as using polyethylene oxide and polyethylene glycol as standard substances as described later. Moreover, since it is a relative value, it is also important to set conditions in the separation of test components and the creation of a calibration curve. In view of the characteristics of these SEC methods, the present inventors have intensively studied the measurement conditions of the SEC method in order to increase the accuracy of calculation of the Z average molecular weight, weight average molecular weight and polydispersity of polysorbate 80.

In this embodiment, the weight average molecular weight, Z average molecular weight, and polydispersity of polysorbate 80 in the ophthalmic composition are measured as follows.
(Preparation of calibration curve solution)
1. Polyethylene oxide (Tosoh Corporation) and polyethylene glycol (Wako Pure Chemical Industries, Ltd.) having a molecular weight of several hundred thousand to several hundreds are used as standard substances. Polyethylene oxide and polyethylene glycol as standard substances have three types with molecular weights of several hundred thousand, two types with molecular weights of tens of thousands, two types with molecular weights of thousands, and molecular weights of hundreds. It is preferable to use one type. More preferably, polyethylene oxide having a molecular weight of 580000, 255000, 146000, 44900, 27000 and polyethylene glycol having a molecular weight of 8000, 1000, 600 are used and divided into molecular weights of 580000, 146000, 27000, 1000 and molecular weights of 255000, 44900, 8000, 600. Combine so that the elution positions do not overlap.
2. An aqueous solution with a standard substance concentration of 0.1 w / v% is prepared and used as a standard solution. Setting the concentration of the standard substance to 0.1 w / v% is very important for suppressing the relative standard deviation of the Z average molecular weight, the weight average molecular weight, and the polydispersity.
3. A standard solution of 1.0 mL is accurately taken, and a solution obtained by accurately adding 4.0 mL of methanol is used as a calibration curve solution.
(Preparation of sample solution)
4). Take 1.0 mL of the test solution accurately, and accurately add 4.0 mL of methanol as the sample solution.
(Measurement by liquid chromatograph)
5. Each calibration curve solution and sample solution are measured with a liquid chromatograph (Agilent 1200 series, manufactured by Agilent Technologies).
6). The columns are manufactured by Tosoh Corporation. TSK-Gelα-4000 (exclusion limit molecular weight of about 400,000) and TSK-Gelα-2500 (exclusion limit molecular weight of about 5000) filled with hydrophilic vinyl polymer (both columns have an inner diameter of 7.8 mm, 300 mm long) are connected and installed one by one in this order. The column temperature is 40.0 ° C. It is very important to keep 40.0 ° C. constant in order to suppress the relative standard deviation of Z average molecular weight, weight average molecular weight, and polydispersity.
7). As the eluent, a mixed solution in which the volume of methanol is 4.0 times the 0.10 mol / L sodium chloride aqueous solution is prepared for each measurement and used. The inclusion of sodium chloride in the eluent to suppress the interaction between sample molecules or between the sample molecules and the filler is very important for suppressing the relative standard deviation of the Z average molecular weight, weight average molecular weight, and polydispersity. It is.
8). The flow rate is 0.5 mL / min.
9. The injection volume is 50 μL. Filter through a 0.45 μm filter prior to injection.
10. The calibration curve solution and the sample solution were measured in this order, and the analysis cycle was 60 minutes for the calibration curve solution and 90 minutes for the sample solution. It is very important to continuously measure the calibration curve solution and the sample solution without interrupting the measurement in order to suppress the relative standard deviation of the Z average molecular weight, the weight average molecular weight, and the polydispersity.
11. The detector is a differential refractive index detector, and the detector temperature is 35.0 ° C.
(Calculation of Z average molecular weight, weight average molecular weight and polydispersity)
12 The obtained chromatogram is analyzed with an SEC analyzer, and the Z-average molecular weight and the weight-average molecular weight are calculated for the range sandwiched between the chromatogram curve and the baseline. The elution time and molecular weight value of each peak are plotted from the calibration curve solution, approximated by a linear equation to obtain a calibration curve, and the correlation coefficient is 0.99 or more. Furthermore, in order to reduce errors in chromatogram analysis processing, the obtained peaks are vertically divided at intervals of 0.1 minutes or more and less than 0.001 minutes to calculate the average molecular weight.
13. The polydispersity is calculated from the formula of _Mz / _Mw . 4. above. Measure the sample solution of the process indicated by 3 times, and adopt the average value of the Z average molecular weight, weight average molecular weight or polydispersity obtained in each as the Z average molecular weight, weight average molecular weight or polydispersity of the present application, respectively. To do.

The relative standard deviation of the average molecular weight in the generally known SEC method is calculated by the following formulas A and B and is about 4 to 5%. Since the relative standard deviation of polydispersity is less than 5% under the above SEC measurement conditions, it can be said that the measurement conditions are appropriate. The polydispersity in the present application is measured and calculated so that the relative standard deviation is less than 5%. When the above-mentioned reagents, columns, liquid chromatographs and the like are not available, measurements can be performed using alternatives equivalent to these. However, it is necessary to measure so that the relative standard deviation of polydispersity is less than 5%. When the relative standard deviation is 5% or more, it is necessary to suppress the relative standard deviation within the examination range of the measurement conditions normally performed. In order to suppress the relative standard deviation in the study by the present inventors, it is important that the above conditions are satisfied with respect to the concentration of the standard substance, the column temperature, the composition of the eluent, and the analysis cycle of the calibration curve solution and the sample solution. It was.

  The content of the component (A) in the ophthalmic composition according to the present embodiment is not particularly limited, and is appropriately set according to the type and content of the component (B) to be used in combination. As content of (A) component, it is preferable that it is 0.0001-8 w / v% on the basis of the total amount of an ophthalmic composition, for example, and it is more preferable that it is 0.0001-4 w / v%, More preferably, it is 0.0005 to 2 w / v%, and particularly preferably 0.01 to 1 w / v%. The content of the component (A) is suitable from the viewpoint of the effect of suppressing the adsorption of foreign matter to the cornea or alleviating the feeling of foreign matter in the eye.

(B) component (B) A component is a cooling agent. As the component (B), one type may be used alone, or two or more types may be used in arbitrary combination.

  The refreshing agent used in the ophthalmic composition according to the present embodiment is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Examples of the refreshing agent include terpenoids, essential oils containing terpenoids (eg, eucalyptus oil, bergamot oil, peppermint oil, fennel oil, rose oil, cinnamon oil, spearmint oil, camphor oil, cool mint and mint oil). Can be mentioned. Examples of terpenoids include menthol, menthone, camphor (also referred to as “camphor” or “camphor”), borneol (also referred to as “ryuuno” or “carp”), geraniol, nerol, cineol, citronellol, carvone, anethole, Examples include eugenol, limonene, linalool and linalyl acetate. The terpenoid may be any of d-form, l-form and dl-form, and examples thereof include l-menthol, d-menthol, dl-menthol, dl-camphor, d-camphor, dl-borneol and d-borneol. However, optical isomers may not exist depending on terpenoids such as geraniol, nerol and cineol. From the viewpoint of the effect of suppressing the adsorption of foreign matter to the cornea or alleviating the feeling of foreign matter in the eye, the refreshing agent preferably contains at least one selected from the group consisting of menthol, camphor, borneol and geraniol. It is particularly preferred to contain at least one selected from the group consisting of, l-menthol, dl-camphor, d-camphor and d-borneol.

  Content of the refreshing agent in the ophthalmic composition which concerns on this embodiment is not specifically limited, It sets suitably according to the kind of cooling agent, the kind and content of (A) component to use together. The content of the refreshing agent can be measured as a terpenoid. For example, based on the total amount of the ophthalmic composition, the total content of the refreshing agent (as the terpenoid) is 0.00005 to 0.5 w / v. %, More preferably 0.0001 to 0.3 w / v%, still more preferably 0.0005 to 0.2 w / v%, and 0.001 to 0.1 w / v. % Is particularly preferred. The content of the refreshing agent is suitable from the viewpoint of the effect of suppressing the adsorption of foreign matter to the cornea or alleviating the feeling of foreign matter in the eye.

  In the ophthalmic composition according to the present embodiment, the content ratio of the refreshing agent relative to the component (A) is not particularly limited, and is appropriately set according to the type of the refreshing agent. As a content ratio of the cooling agent with respect to (A) component, the total content of a cooling agent is 0.0001-100 with respect to 1 mass part of content of (A) component contained in an ophthalmic composition, for example. The amount is preferably part by mass, more preferably 0.001 to 80 parts by mass, still more preferably 0.005 to 60 parts by mass, and particularly preferably 0.01 to 50 parts by mass. The content ratio of the refreshing agent relative to the component (A) is preferable from the viewpoint of the effect of suppressing the adsorption of foreign matter to the cornea or alleviating the feeling of foreign matter in the eye.

  The ophthalmic composition according to this embodiment preferably further contains a buffer. Thereby, the pH of the ophthalmic composition can be adjusted, and the effects of the present invention can be exhibited more remarkably.

  The buffer is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Examples of the buffer include borate buffer, phosphate buffer, carbonate buffer, citrate buffer, acetate buffer, tris buffer, aspartic acid, aspartate, edetate, and the like. These buffering agents may be used alone or in any combination of two or more. Examples of the boric acid buffer include boric acid or a salt thereof (alkali metal borate, alkaline earth metal borate, etc.). Examples of the phosphate buffer include phosphoric acid or a salt thereof (such as an alkali metal phosphate or an alkaline earth metal phosphate). Examples of the carbonate buffer include carbonic acid or a salt thereof (an alkali metal carbonate, an alkaline earth metal carbonate, etc.). Examples of the citrate buffer include citric acid or salts thereof (alkali metal citrate, alkaline earth metal citrate, etc.). A borate or phosphate hydrate may be used as the borate buffer or phosphate buffer. As a more specific example, boric acid or a salt thereof (sodium borate, potassium tetraborate, potassium metaborate, ammonium borate, borax, etc.); as a phosphate buffer, phosphoric acid or a salt thereof Salt (disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, trisodium phosphate, tripotassium phosphate, calcium monohydrogen phosphate, calcium dihydrogen phosphate, etc.); Or a salt thereof (sodium bicarbonate, sodium carbonate, ammonium carbonate, potassium carbonate, calcium carbonate, potassium bicarbonate, magnesium carbonate, etc.); citric acid or a salt thereof (sodium citrate, potassium citrate, citric acid, etc.) Acid calcium, sodium dihydrogen citrate, disodium citrate, etc.); acetic acid Agents as, acetic acid or a salt thereof (ammonium acetate, potassium acetate, calcium acetate, sodium acetate, etc.); aspartic acid or a salt thereof (sodium aspartate, magnesium aspartate, potassium aspartate, etc.) and the like. Among these buffering agents, boric acid buffering agents (for example, a combination of boric acid and borax) or phosphoric acid buffering agents (for example, a combination of disodium hydrogen phosphate and sodium dihydrogen phosphate) are preferable. A borate buffer is more preferable.

  When a buffering agent is blended in the ophthalmic composition according to the present embodiment, the content thereof includes the type of the buffering agent, the type and content of other blending components, the use of the ophthalmic composition, the formulation form, the method of use, etc. It is set appropriately according to As the content of the buffering agent, for example, based on the total amount of the ophthalmic composition, the total content of the buffering agent is preferably 0.001 to 15 w / v%, and 0.01 to 10 w / v%. It is more preferable that it is 0.05-7.5 w / v%, and it is especially preferable that it is 0.1-5 w / v%.

  The ophthalmic composition according to this embodiment preferably further contains a chelating agent. As a result, the ophthalmic composition can be used stably for a long period of time, and the effects of the present invention can be exhibited more remarkably.

  The chelating agent is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Examples of chelating agents include ethylenediaminediacetic acid (EDDA), ethylenediaminetriacetic acid, ethylenediaminetetraacetic acid (edetic acid, EDTA), N- (2-hydroxyethyl) ethylenediaminetriacetic acid (HEDTA), and diethylenetriaminepentaacetic acid (DTPA). Can be illustrated. Of these chelating agents, ethylenediaminetetraacetic acid is preferred. These chelating agents may be used alone or in any combination of two or more.

  When a chelating agent is blended in the ophthalmic composition according to this embodiment, the content depends on the type of chelating agent, the type and content of other blending components, the use of the ophthalmic composition, the dosage form, the method of use, etc. It is set accordingly. As content of a chelating agent, it is preferable that the total content of a chelating agent is 0.0001-2 w / v% on the basis of the total amount of ophthalmic composition, for example, and is 0.0004-1.5 w / v. %, More preferably 0.0008 to 1 w / v%, and particularly preferably 0.001 to 0.8 w / v%.

  The pH of the ophthalmic composition according to the present embodiment is not particularly limited as long as it is within a pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable range. The pH of the ophthalmic composition is 4.0 to 9.5, preferably 4.5 to 9.0, and more preferably 5.0 to 8.5. When the pH is in the above range, there is little irritation to the eye when the ophthalmic composition is used, and the adsorption of foreign matter to the cornea tends to be further suppressed to further alleviate the feeling of foreign matter in the eye.

  The ophthalmic composition according to this embodiment preferably further contains an isotonic agent. Thereby, the osmotic pressure of the ophthalmic composition can be adjusted, and the effects of the present invention can be exhibited more remarkably. The isotonic agent is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Examples of isotonic agents include disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, sodium hydrogen sulfite, sodium sulfite, potassium chloride, calcium chloride, sodium chloride, magnesium chloride, potassium acetate, acetic acid. Sodium, sodium hydrogen carbonate, sodium carbonate, sodium thiosulfate, magnesium sulfate, glycerin, propylene glycol, polyethylene glycol, glucose, mannitol, sorbitol and the like can be mentioned. Among these isotonic agents, glycerin, propylene glycol, polyethylene glycol, glucose, sodium chloride, potassium chloride, calcium chloride or magnesium chloride are preferable, sodium chloride, potassium chloride or propylene glycol is more preferable, and sodium chloride is particularly preferable. . These tonicity agents may be used alone or in any combination of two or more.

  When the ophthalmic composition which concerns on this embodiment contains an isotonic agent, the content is suitably set according to the kind of tonicity agent, the kind and content of other containing components, etc. As the content of the tonicity agent, for example, the total content of the tonicity agent is preferably 0.001 to 10 w / v% based on the total amount of the ophthalmic composition, and 0.01 to 5 w. / V% is more preferable, and 0.05 to 3 w / v% is still more preferable.

  The osmotic pressure of the ophthalmic composition according to the present embodiment is not particularly limited as long as it is within a range acceptable for a living body. The osmotic pressure ratio of the ophthalmic composition is, for example, preferably 0.5 to 5.0, more preferably 0.6 to 3.0, and further preferably 0.7 to 2.0. Preferably, it is 0.8-1.6. The osmotic pressure can be adjusted by a method known in the art using an inorganic salt, a polyhydric alcohol, a sugar alcohol or a sugar. The osmotic pressure ratio is the ratio of the osmotic pressure of the sample to 286 mOsm (0.9 w / v% sodium chloride aqueous solution) based on the 16th revised Japanese Pharmacopoeia. Measure with reference to (freezing point depression method). In addition, about the standard solution for osmotic pressure ratio measurement (0.9 w / v% sodium chloride aqueous solution), after drying sodium chloride (Japanese Pharmacopoeia standard reagent) at 500-650 degreeC for 40-50 minutes, it is in a desiccator (silica gel). It is allowed to cool, and 0.900 g is accurately weighed and dissolved in purified water to prepare exactly 100 mL, or a commercially available standard solution for osmotic pressure ratio measurement (0.9 w / v% sodium chloride aqueous solution) can be used. .

  The ophthalmic composition according to this embodiment preferably further contains a thickener. Thereby, the viscosity of the ophthalmic composition can be adjusted, and the effect of the present application can be exhibited more remarkably.

  Examples of the thickener include polyvinyl alcohol (completely or partially saponified product), polyvinylpyrrolidone (K25, K30, K90, etc.), carboxyvinyl polymer, cellulose derivatives [methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose. (2208, 2906, 2910, etc.), carboxymethylcellulose, carboxyethylcellulose, nitrocellulose or their salts], polyethylene glycol (Macrogol 300, Macrogol 400, Macrogol 1500, Macrogol 4000, Macrogol 6000, etc.), chondroitin Sodium sulfate, sodium hyaluronate, gum arabic, gellan gum, tragacanth, dextran (40 70), glucose, sorbitol, etc., preferably polyvinyl alcohol (completely or partially saponified product), polyvinylpyrrolidone (K25, K30, K90), carboxyvinyl polymer, cellulose derivative [methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, Hydroxypropylmethylcellulose (2208, 2906, 2910), carboxymethylcellulose or a salt thereof, etc.], polyethylene glycol (Macrogol 300, Macrogol 400, Macrogol 4000, Macrogol 6000, etc.) or dextran (70), more preferably. Is polyvinyl alcohol (completely or partially saponified), polyvinylpyrrolidone (K25, K30, K90), carboxyvinyl polymer, Chill cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose (2208, 2906, 2910), carboxymethyl cellulose or a salt thereof, polyethylene glycol (Macrogol 300, Macrogol 400, Macrogol 4000, Macrogol 6000) or dextran (70). From the viewpoint of the effect of suppressing foreign matter adsorption to the cornea or alleviating the foreign body sensation of the eye, polyvinylpyrrolidone, hydroxyethylcellulose or hydroxypropylmethylcellulose is more preferred, and polyvinylpyrrolidone is particularly preferred. These thickeners may be used alone or in any combination of two or more.

  When the ophthalmic composition which concerns on this embodiment contains a viscous agent, the content is suitably set according to the kind of viscous agent, the kind and content, etc. of another content component. As the content of the viscous agent, for example, the total content of the viscous agent is preferably 0.0001 to 5 w / v%, based on the total amount of the ophthalmic composition, and 0.0005 to 3 w / v. % Is more preferable, 0.001 to 2 w / v% is further preferable, and 0.01 to 1 w / v% is particularly preferable.

  The viscosity of the ophthalmic composition according to the present embodiment is not particularly limited as long as it is within a range acceptable for a living body. The viscosity at 25 ° C. measured with a rotational viscometer (RE550 type viscometer, manufactured by Toki Sangyo Co., Ltd., rotor: 1 ° 34 ′ × R24) is preferably 0.1 to 1000 mPa · s, for example, 0.5 More preferably, it is -100mPa * s, and it is still more preferable that it is 1-50mPa * s.

The ophthalmic composition according to the present embodiment may contain an appropriate amount of various pharmacologically active components or physiologically active components in addition to the above components as long as the effects of the present invention are not hindered. Such components are not particularly limited, and examples thereof include active ingredients in various pharmaceuticals described in the OTC Drug Manufacturing and Sales Approval Standards 2012 edition (supervised by the Japanese Society for Regulatory Science). Specifically, the following components are listed as components used in ophthalmic drugs.
Antiallergic agents: cromoglycate, amlexanox, ibudilast, suplatast, pemirolast potassium, tranilast, olopatadine hydrochloride, levocabastine hydrochloride and acitazanolast.
Antihistamines: chlorpheniramine maleate, diphenhydramine hydrochloride, ketotifen fumarate, etc.
Vasoconstrictor (decongestant): tetrahydrozoline hydrochloride, tetrahydrozoline nitrate, naphazoline hydrochloride, naphazoline nitrate, epinephrine, epinephrine hydrochloride, ephedrine hydrochloride, phenylephrine hydrochloride, and dl-methylephedrine hydrochloride.
Anti-inflammatory agents: pranoprofen, glycyrrhizic acid, allantoin, berberine sulfate, berberine chloride, azulene sulfonic acid, ε-aminocaproic acid, zinc sulfate, zinc lactate, lysozyme, salicylic acid, tranexamic acid, licorice and salts thereof.
Eye muscle modulating agent: For example, cholinesterase inhibitor having an active center similar to acetylcholine, specifically, neostigmine methyl sulfate, tropicamide, helenien, atropine sulfate and the like.
Bactericides: Acrinol, cetylpyridinium, benzalkonium chloride, benzethonium chloride, chlorhexidine, polyhexamethylene biguanide, alkyldiaminoethylglycine hydrochloride and the like.
Amino acids: glycine, alanine, γ-aminobutyric acid, aspartic acid, potassium L-aspartate, glutamic acid, arginine, lysine, aminoethylsulfonic acid (taurine), chondroitin sulfate, sodium chondroitin sulfate, sodium hyaluronate and alginic acid.
Vitamins: vitamin B ₁ , vitamin B ₂ (flavin adenine dinucleotide sodium), niacin (nicotinic acid and nicotinamide), pantothenic acid, panthenol, vitamin B ₆ (pyridoxine, pyridoxal and pyridoxamine), biotin, folic acid, vitamin B ₁₂ (cyanocobalamin, hydroxocobalamin, methylcobalamin and adenosylcobalamin), retinol acetate, retinol palmitate, tocopherol acetate and the like.
Other: For example, sulfamethoxazole, sulfamethoxazole sodium and the like.

In the ophthalmic composition according to the present embodiment, various additives are appropriately selected according to a conventional method according to the use or formulation form within a range that does not impair the effects of the invention, and one or more are selected. An appropriate amount may be contained in combination. Examples of these additives include various additives described in Pharmaceutical Additives Encyclopedia 2007 (edited by Japan Pharmaceutical Additives Association). Typical additives include the following additives.
Carrier: An aqueous carrier such as water or hydrous ethanol.
Sugars: for example, glucose, cyclodextrin and the like.
Sugar alcohols: For example, xylitol, sorbitol, mannitol and the like. These may be any of d-form, l-form and dl-form.
Nonionic surfactants: monouraric acid POE (20) sorbitan (polysorbate 20), monopalmitic acid POE (20) sorbitan (polysorbate 40), monostearic acid POE (20) sorbitan (polysorbate 60) and tristearic acid POE ( 20) POE sorbitan fatty acid ester such as sorbitan (polysorbate 65); POE such as POE (40) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 40) and POE (60) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 60) Hardened castor oil; POE castor oil such as POE (10) castor oil (polyoxyethylene castor oil 10) and POE (35) castor oil (polyoxyethylene castor oil 35); POE alkyl ether such as POE (9) lauryl ether ; POE 20) POE-POP alkyl ethers such as POP (4) cetyl ether; POE (54) POP (39) glycol, POE (120) POP (40) glycol, POE (160) POP (30) glycol, POE (196) Polyoxyethylene / polyoxypropylene block copolymers such as POP (67) glycol (poloxamer 407, Pluronic F127) and POE (200) POP (70) glycol; monostearate polyethylene glycol such as polyoxyl 40 stearate; In the compounds exemplified above, the numbers in parentheses indicate the number of added moles.
Amphoteric surfactants: N- [2-[[2- (alkylamino) ethyl] amino] ethyl] glycine and its salts (also called alkyldiaminoethylglycine or alkylpolyaminoethylglycine) and the like.
Negative surfactant: alkylbenzene sulfonate, alkyl sulfate, polyoxyethylene alkyl sulfate, α-sulfo fatty acid ester salt, α-olefin sulfonic acid and the like.
Positive surfactant: benzalkonium chloride, benzethonium chloride, etc.
Antiseptics, bactericides or antibacterials: for example, zinc chloride, alkyldiaminoethylglycine hydrochloride, sodium benzoate, ethanol, benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorobutanol, sorbic acid, potassium sorbate, dehydroacetic acid Sodium, methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate, oxyquinoline sulfate, phenethyl alcohol, benzyl alcohol, biguanide compounds (specifically, polyhexamethylene biguanide, polyhexanide hydrochloride, etc.), Glow Kill (trade name, manufactured by Rhodia).
Stabilizers: trometamol, sodium formaldehyde sulfoxylate (Longalite), tocopherol, sodium pyrosulfite, monoethanolamine, aluminum monostearate, glyceryl monostearate, dibutylhydroxytoluene, sodium edetate, etc.
Base: for example, octyldodecanol, titanium oxide, potassium bromide, paraffin, plastibase, lanolin, propylene glycol and the like.

  The ophthalmic composition according to the present embodiment is prepared by adding the above components (A) and (B) and other components as necessary to the carrier so as to have a desired content. Specifically, for example, the components can be dissolved or suspended in purified water, adjusted to a predetermined pH and osmotic pressure, and sterilized by filtration sterilization or the like.

  The content of water in the ophthalmic composition according to this embodiment is preferably 85 w / v% or more, more preferably 90 w / v% or more, and 92 w / v based on the total amount of the ophthalmic composition. % Or more, more preferably 94 w / v% or more, and particularly preferably 96 w / v% or more. As the water used in the ophthalmic composition, water that is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable may be used. Specific examples of such water include distilled water, ordinary water. Examples thereof include water, purified water, sterilized purified water, water for injection, and distilled water for injection.

  The ophthalmic composition according to the present embodiment is provided by being accommodated in an arbitrary container. The container for storing the ophthalmic composition is not particularly limited. For example, the container may be made of glass or plastic. Preferably it is made of plastic. Examples of the plastic include, for example, polyethylene terephthalate, polyarylate, polyethylene naphthalate, polycarbonate, polyethylene, polytetrafluoroethylene, polypropylene, polybutylene terephthalate, polyimide, polymethylpentene, and copolymers of monomers constituting these, and these What mixed 2 or more types including a material is mentioned. Polyethylene terephthalate is preferable. In addition, the container that stores the ophthalmic composition may be a transparent container that can visually recognize the inside of the container, or an opaque container that is difficult to visually recognize the interior of the container. A transparent container is preferable. Here, the “transparent container” includes both a colorless transparent container and a colored transparent container. The ophthalmic composition may be housed and used in a multi-dose form that can be used repeatedly, for example, in a colored transparent plastic container, or may be housed and used in a single-use form.

  The ophthalmic composition according to this embodiment can be used as a pharmaceutical preparation or a quasi-drug preparation, and is a so-called eye drop [however, the eye drop includes an eye drop that can be applied while wearing a contact lens. ] In addition to artificial tears and eye wash [however, eye wash contains eye wash that can be washed while wearing contact lenses. ], Contact lens composition [contact lens mounting solution, contact lens care composition (contact lens disinfectant, contact lens preservative, contact lens cleaning agent, contact lens cleaning preservative), etc.] . Preferable examples of the present invention include eye drops, artificial tears, eye washes, and contact lens mounting liquids, and eye drops and artificial tears are particularly preferable examples. In addition, when using the said ophthalmic composition as a composition for contact lenses, it is applicable to all contact lenses including a hard contact lens and a soft contact lens, and can also be applied in the state worn with respect to the said contact lens. Is possible. The ophthalmic composition according to the present embodiment is also suitable for application to a contact lens from the viewpoint of suppressing the adsorption of foreign matter to the cornea due to compression or the like by wearing the contact lens or alleviating the feeling of foreign matter on the eye.

  The ophthalmic composition is applicable to any contact lens as long as it is a known contact lens. From the viewpoint of a large lens diameter and a large contact area with the eye, it is particularly preferably applied to a soft contact lens. Soft contact lenses (SCL) are classified by the method described in ISO18369-1: 2006 and ISO18369-1: AMENDENT1, for example.

  The ophthalmic composition according to the present embodiment can not only improve subjective symptoms but also suppress the adsorption of foreign matter to the cornea in order to relieve the feeling of foreign matter in the eye. A foreign body sensation means a subjective symptom (discomfort, irritation) of the eyes that is tingling or tingling, and may be caused by dry eyes, use of contact lenses, or allergic conjunctivitis. Foreign body sensation is further enhanced by accompanying inflammation. The ophthalmic composition according to the present embodiment can be applied for the purpose of preventing or treating various symptoms accompanied by a foreign body sensation. From the viewpoint of suppressing the adsorption of foreign substances, it is suitable for foreign body sensations caused by allergic conjunctivitis, contact lens wearing, eye contact, etc. That is, the said ophthalmic composition is used suitably as a foreign material feeling mitigation agent. In other words, the foreign substance sensation mitigating agent includes the ophthalmic composition.

(Method of imparting a foreign substance easing effect)
In another embodiment of the present invention, by blending (A) polysorbate 80 and (B) a refreshing agent, the ophthalmic composition is imparted with an alleviating effect on the foreign body sensation of the eye,
The present invention provides a method wherein the polydispersity of the polysorbate 80 in the ophthalmic composition is 1.00 to 1.26.

  According to the ophthalmic composition according to the present embodiment, the combination of polysorbate 80 having a polydispersity in the ophthalmic composition of 1.00 to 1.26 and a refreshing agent suppresses foreign matter adsorption to the cornea. By doing so, it is possible to further alleviate the feeling of foreign objects in the eye.

(Production method)
In the production of the ophthalmic composition according to the present embodiment, by adsorbing polysorbate 80 having a polydispersity of 1.00 to 1.26 and a cooling agent in the ophthalmic composition, foreign matter adsorption to the cornea is achieved. It is suggested that the inhibitory effect (inhibitory action) can contribute to the provision of a preparation that is maintained or improved.

  Hereinafter, the present invention will be described in more detail based on examples, but the present invention is not limited to these examples.

Test Example 1 Measurement of the amount of foreign matter adsorbed on corneal epithelial cells (1) Test method Test solutions A and B shown in Tables 2 and 3 using polysorbate 80 having different polydispersities shown in Table 1 respectively. And the polydispersity of polysorbate 80 in each test solution was measured. Thereafter, each test solution to which fluorescently labeled albumin (final concentration 0.2%) was added was added to the culture medium, and the influence on the foreign substance adsorption to the corneal epithelial cells was evaluated.

Human corneal epithelial cell line HCE-T (RIKEN BioResource Center, No. RCB2280) is cultured in each well so as to be 3.0 × 10 ⁵ cells / well in a 48-well microplate (manufactured by Corning). 600 μL each of the medium was seeded and cultured at 37 ° C. under 5% CO ₂ for 24 hours. After culturing, the culture medium was removed by suction, 200 μL of each test solution to which albumin (final concentration 0.2%) fluorescently labeled with fluorescein isothiocyanate (FITC) was added was placed and allowed to stand at room temperature for 60 minutes. After the treatment, the solution in the well was removed by suction, and 600 μL of phosphate buffer was added to each well. After removing the solution in the well by suction and washing, 200 μL of a phosphate buffer solution was added, and a fluorescence plate reader (Fluoroskan Ascent CF, manufactured by MTX Labsystems) was used at an excitation wavelength of 495 nm / emission wavelength of 520 nm. The fluorescence value was measured. Based on a calibration curve between the amount of foreign matter (albumin amount) and fluorescence value prepared in advance, the obtained fluorescence value was converted into the amount of foreign matter. From the amount of foreign matter obtained, the foreign matter adsorption suppression rate (%) was calculated based on the formula (1). And the increase / decrease in the suppression rate of a foreign material adsorption | suction was computed based on Formula (2). In the formula (1), the control refers to a culture medium containing neither the component (A) nor the component (B).
Inhibition rate of foreign matter (%) = [1-{(amount of foreign matter in each test solution) / (amount of foreign matter in control)}] × 100 (1)
Increase / decrease of foreign matter adsorption suppression rate = {foreign matter adsorption suppression rate when using test solution B (%)} − {foreign matter adsorption suppression rate when using test solution A (%)} Equation ( 2)
(2) Test results The results are shown in Table 4. Combining various components (A) and (B) having different polydispersities reduces the effect of suppressing foreign matter adsorption in components (A) having a polydispersity of 1.28 or more in the test solution. (Comparative Examples 1-2) In (A) component whose polydispersity in a test liquid is less than 1.28, it was shown that the inhibitory effect of a foreign material adsorption improves (Examples 1-4).

Test Example 2 Sensory test: Effect of improving foreign body feeling (1) Test method Each eye drop was prepared according to the conventional method according to Table 5 below, and the polydispersity of polysorbate 80 in each eye drop was measured. Each eye drop was filled in a polyethylene terephthalate container. Eye drops that contain (A) polysorbate 80 and (B) 1-menthol, and the polydispersity of polysorbate 80 in the eye drops is less than 1.21 for subjects who are usually aware of a foreign body sensation in the eyes. Examples 5 to 7) for the left eye, an eye drop containing (A) polysorbate 80 and (B) 1-menthol, and having a polydispersity of polysorbate 80 in the eye drop of 1.34 or more (Comparative Example 3) ) Was administered to the right eye once. Then, using a 10 cm straight line with a scale of 0 to 100 shown in Table 6, evaluation of the foreign body sensation of the eye after instillation was performed by the Visual Analog Scale method (VAS method). In addition, evaluation of a foreign body feeling was performed separately for the case where five contact lens non-wearers were subjects and the case where three contact lens wearers were subjects.
(2) Test results The results are shown in Table 5. When the eye drops of Examples 5 to 7 containing (A) polysorbate 80 and (B) 1-menthol and having a polydispersity of polysorbate 80 in the eye drops of less than 1.34 are used, significant foreign body sensation It was confirmed to show an improvement effect.

Claims (8)

Polysorbate 80,
A cooling agent,
An ophthalmic composition comprising:
The polydispersity of the polysorbate 80 in the ophthalmic composition is 1.00 to 1.26,
An ophthalmic composition wherein the refreshing agent comprises menthol . The ophthalmic composition according to claim 1 , wherein the total content of the refreshing agent is 0.00005 to 0.5 w / v% based on the total amount of the ophthalmic composition.   The ophthalmic composition according to claim 1 or 2, wherein the total content of the refreshing agent is 0.0001 to 100 parts by mass with respect to 1 part by mass of the polysorbate 80 contained in the ophthalmic composition. object.   The ophthalmic composition according to any one of claims 1 to 3, which is an eye drop. The ophthalmic composition according to any one of claims 1 to 4, which is applied to a contact lens.   A foreign substance sensation alleviating agent comprising the ophthalmic composition according to any one of claims 1 to 5. The ophthalmic composition, polysorbate 80, which comprises mixing the cooling agent, and a method of imparting relaxation effect of foreign body sensation in the ophthalmic composition,
The polydispersity of the polysorbate 80 in the ophthalmic composition is 1.00 to 1.26,
The method wherein the refreshing agent comprises menthol . A method of providing the ophthalmic composition with an inhibitory effect on foreign matter adsorption to the cornea, comprising blending polysorbate 80 and a refreshing agent to the ophthalmic composition,
The polydispersity of the polysorbate 80 in the ophthalmic composition is 1.00 to 1.26,
The method wherein the refreshing agent comprises menthol.